Gwenn Hansen, Chief Scientific Officer at Nurix Therapeutics, Inc. (NRIX), sold 4,111 shares at $23.87 ($100K) on 2026-08-04, disclosed to the SEC on 2026-08-05.
Scheduled sale ($100k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $23.87 | 1,500 | $36K | 35.8% |
| 2 | $24.64 | 2,611 | $64K | 64.2% |
| Total | $24.36 avg | 4,111 | $100K | 100% |
| Filing → |
| NRIX | SELL | 2026-07-30 | $90K | — | Filing → |
| NRIX | SELL | 2026-06-25 | $108K | — | Filing → |
| NRIX | SELL | 2026-04-30 | $53K | — | Filing → |